Oxurion (voorheen Thrombogenics)

Beleggen, aandelen kopen in België, informatie, koersen en analyses



Gebruikersavatar
sanderus
Forum elite
Forum elite
Berichten: 4806
Lid geworden op: 07 aug 2012 08:47
Locatie: Fovea Centralis
waarderingen: 9548

Re: Oxurion (voorheen Thrombogenics)

Bericht door sanderus »

Aantal conferenties waar Oxurion aanwezig is.

10/06/2021
BIO Digital

16/06/2021
The JMP Securities Life Sciences Conference

21/06/2021
Kepler Cheuvreux – Belfius Digital Life Science Days

17/08/2021
Integrin-Targeted Drug Discovery Summit - Uncover the Therapeutics Promise of Integrins

28/08/2021
Clinical Trials at the Summit

13/09/2021
H.C. Wainwright 23rd Annual Global Investment Conference

07/10/2021
21st Annual Biotech in Europe Forum (digital)

12/11/2021

AAO 2021 - American Academy of Ophthalmology's annual meeting

22/11/2021
Ophthalmic Drugs – Investigating the unique challenges in ocular drug design & delivery strategy

06/12/2021
International Diabetes Federation (IDF) Virtual Congress 2021
believer liked last!



David1972
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 13 aug 2015 16:48
waarderingen: 272

Re: Oxurion (voorheen Thrombogenics)

Bericht door David1972 »

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)


THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population responding suboptimally to anti-VEGF therapy

Leuven, BE, Boston, MA, US – June 8, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, today announced the completion of patient enrollment into Part A of its two part Phase 2 study (“KALAHARI”) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021.

THR-149, Oxurion’s most advanced drug candidate, is being developed to potentially become the treatment of choice for the up to 40% of DME patients, who respond suboptimally to anti-VEGF therapy. THR-149 acts through inhibition of the plasma kallikrein-kinin (PKaI-Kinin) system, a validated VEGF-independent target for DME.

A single dose Phase 1 study showed that THR-149 was well-tolerated, safe and delivered promising efficacy results, particularly improvements in patients’ Best Corrected Visual Acuity (BCVA) the primary endpoint for registration in DME. A rapid onset of action was observed from Day 1, across all doses, with an increasing average improvement in BCVA of up to 7.5 letters at Day 14. Importantly, this visual gain was maintained with an average improvement in BCVA of 6.4 letters at Day 90.
The Phase 2 KALAHARI study is a two part, randomized, prospective, multi-center study assessing multiple (3) injections of THR-149 in DME patients who suboptimally respond to anti-VEGF therapy. In Part A of the study, three dose levels of THR-149, each administered in 3 monthly intravitreal injections, are being tested in at least 18 patients to select the optimal dose for Part B.

Tom Graney, CFA, Chief Executive Officer of Oxurion, comments, “We are very pleased to announce the completion of patient enrollment into Part A of our Phase 2 study evaluating THR-149 for the treatment of DME, particularly given the challenges posed by the continuing Covid-19 situation. This milestone positions us to report the important initial Part A data in the second half of the year. These data, if positive, will provide proof of concept and be a significant derisking event for the company. This patient population currently does not have adequate treatment options and represents a critical area of unmet medical need in the treatment of diabetic macular edema.”

Part B (n≈104) is the double-masked, active-controlled part of the study with the dose selected from Part A studied against aflibercept as the active comparator. Final topline results from Part B of the study are expected in the first half of 2023.

END

For further information please contact:
Oxurion NV
Wouter Piepers,
Global Head of Investor Relations
& Corporate Communications
Tel: +32 478 33 56 32
wouter.piepers@oxurion.com

EU
Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/Frazer Hall
Tel: +44 20 7638 9571
oxurion@citigatedewerogerson.com

US
Westwicke, an ICR Company
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Oxurion is aiming to build the leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics:

THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for the 40% of DME patients who respond suboptimally to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME. The company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 in DME patients who previously responded suboptimally to anti-VEGF therapy.

THR-687 is a pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients. Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020. THR-687 is expected to enter a Phase 2 clinical trial in mid-2021. THR-687, also has the potential to deliver improved treatment outcomes for patients with wet AMD and RVO.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. More information is available at www.oxurion.com.
pingping liked last!

David1972
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 13 aug 2015 16:48
waarderingen: 272

Re: Oxurion (voorheen Thrombogenics)

Bericht door David1972 »

BM FN) Oxurion heeft alle patiënten voor deel A van de Fase 2 studie met THR-149 voor de behandeling van Diabetisch Maculair Oedeem (DMO) gerekruteerd. Dit liet het biotechbedrijf dinsdagochtend weten.

De eerste onderzoeksdata worden in de tweede helft van dit jaar verwacht. En indien deze positief zijn, dan meent CEO Tom Graney dat hiermee een belangrijk deel van de risico’s voor Oxurion wegvallen.
Xem liked last!

Gebruikersavatar
noobs_inc
Forum gebruiker
Forum gebruiker
Berichten: 154
Lid geworden op: 17 feb 2019 11:10
waarderingen: 146

Re: Oxurion (voorheen Thrombogenics)

Bericht door noobs_inc »

Zullen dan toch wat vertraging opgelopen hebben in deze tijden.
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.

believer
Forum elite
Forum elite
Berichten: 5471
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4657

Re: Oxurion (voorheen Thrombogenics)

Bericht door believer »

VWarena liked last!

believer
Forum elite
Forum elite
Berichten: 5471
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4657

Re: Oxurion (voorheen Thrombogenics)

Bericht door believer »


Gebruikersavatar
sanderus
Forum elite
Forum elite
Berichten: 4806
Lid geworden op: 07 aug 2012 08:47
Locatie: Fovea Centralis
waarderingen: 9548

Re: Oxurion (voorheen Thrombogenics)

Bericht door sanderus »

noobs_inc schreef:
08 jun 2021 08:01
Zullen dan toch wat vertraging opgelopen hebben in deze tijden.
Noobs,

Er is inderdaad vertraging maar dit gaat uiteindelijk nog goed meevallen.

Ik ga ervan uit dat niet enkel de laatste patient in de studie zit maar deze tevens reeds zijn 3de injectie heeft gekregen  en misschien reeds het primair eindpunt werd bepaald  1 maand na de 3de injectie omdat:
je maar zeker bent dat de laatste patient in de studie zit als deze zijn laatste injectie heeft gekregen. Dit is een oudere bevolkingsgroep en soms gaan patienten " verloren". Dit kan door ziekte zijn , sterfte zijn of gewoon niet komen opdagen voor de controles. Ik las van Kodiak Sciences dat er 10% patienten verloren waren gegaan. Na die 3de injectie komt een maand later het onderzoek waarbij het primair eindpunt (BCVA) wordt vastgesteld.
Screenshot_20210608-084208_Samsung Notes.jpg
Ik denk dat we de resultaten ergens vanaf eind augustus mogen verwachten.
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
noobs_inc liked last!

believer
Forum elite
Forum elite
Berichten: 5471
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4657

Re: Oxurion (voorheen Thrombogenics)

Bericht door believer »


Hoebeet
Forum elite
Forum elite
Berichten: 2109
Lid geworden op: 14 jun 2013 11:28
waarderingen: 1409

Re: Oxurion (voorheen Thrombogenics)

Bericht door Hoebeet »

Ik ga voorzichtigjes er tóch maar vanuit, dat het vanaf vandaag, plús 3 maanden wordt;
met een additionele maand data-analyse: ergens in Oktober dus.
sanderus liked last!

Gebruikersavatar
buffalo1
Forum veteraan
Forum veteraan
Berichten: 1808
Lid geworden op: 14 aug 2012 10:52
waarderingen: 1010

Re: Oxurion (voorheen Thrombogenics)

Bericht door buffalo1 »

believer schreef:
08 jun 2021 09:32
Kbc de oplichters zijn weer actief

https://www.trivano.com/aandeel/advies- ... 923.advies
Waarom zouden ze dat moeten aanpassen ...
Zijn de resultaten dat tellen.









Plaats reactie